Profound Medical (PROF) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

PROF Stock Forecast

Profound Medical stock forecast is as follows: an average price target of $14.25 (represents a 88.74% upside from PROF’s last price of $7.55) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

PROF Price Target

The average price target for Profound Medical (PROF) is $14.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $16.50 to $12.00. This represents a potential 88.74% upside from PROF's last price of $7.55.

PROF Analyst Ratings

Buy

According to 2 Wall Street analysts, Profound Medical's rating consensus is 'Buy'. The analyst rating breakdown for PROF stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Profound Medical Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 23, 2024	Ben Haynor	Lake Street	-	-	60.47%	118.54%
Jul 15, 2024	Rick Wise	Stifel Nicolaus	-	-	31.15%	58.94%

Row per page

Go to

The latest Profound Medical stock forecast, released on Jul 23, 2024 by Ben Haynor from Lake Street, set a price target of $16.50, which represents a 60.47% increase from the stock price at the time of the forecast ($10.28), and a 118.54% increase from PROF last price ($7.55).

Profound Medical Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$14.25
Last Closing Price	$7.55	$7.55	$7.55
Upside/Downside	-100.00%	-100.00%	88.74%

In the current month, the average price target of Profound Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Profound Medical's last price of $7.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jan 06, 2023	Lake Street	Buy	Buy	Hold
Feb 22, 2022	Raymond James		Outperform	Downgrade

Row per page

Go to

Profound Medical's last stock rating was published by Lake Street on Jan 06, 2023. The company gave PROF a "Buy" rating, the same as its previous rate.

Profound Medical Financial Forecast

Profound Medical Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.86M	$1.26M	$2.04M	$2.02M	$1.36M	$998.00K	$2.54M	$2.63M	$711.00K	$2.85M	$2.23M	$1.04M	$1.10M	$2.17M	$515.35K
Avg Forecast	$24.30M	$21.90M	$19.60M	$17.40M	$9.73M	$7.93M	$5.67M	$4.80M	$4.18M	$3.00M	$2.64M	$2.44M	$1.97M	$2.20M	$2.13M	$2.12M	$2.67M	$2.41M	$2.02M	$1.76M	$2.79M	$3.57M	$2.20M	$2.48M	$2.31M	$1.71M	$737.22K	$892.29K	$2.08M	$1.16M
High Forecast	$32.40M	$29.20M	$26.13M	$23.20M	$12.98M	$10.58M	$7.56M	$6.24M	$4.23M	$4.01M	$3.52M	$3.25M	$2.63M	$2.93M	$2.84M	$2.82M	$3.56M	$2.41M	$2.02M	$1.76M	$2.79M	$3.57M	$2.20M	$2.48M	$2.31M	$1.71M	$737.22K	$892.29K	$2.08M	$1.16M
Low Forecast	$19.08M	$17.20M	$15.39M	$13.66M	$7.64M	$6.23M	$4.45M	$3.36M	$4.13M	$2.36M	$2.07M	$1.91M	$1.55M	$1.73M	$1.68M	$1.66M	$2.10M	$2.41M	$2.02M	$1.76M	$2.79M	$3.57M	$2.20M	$2.48M	$2.31M	$1.71M	$737.22K	$892.29K	$2.08M	$1.16M
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	6	4	4	7	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	0.47%	0.84%	1.00%	0.78%	0.36%	0.71%	1.20%	0.29%	1.24%	1.30%	1.41%	1.23%	1.04%	0.44%

Profound Medical's average Quarter revenue forecast for Jun 23 based on 2 analysts is $2.13M, with a low forecast of $1.68M, and a high forecast of $2.84M. PROF's average Quarter revenue forecast represents a 14.69% increase compared to the company's last Quarter revenue of $1.86M (Mar 23).

Profound Medical EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	6	4	4	7	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-6.22M	$-5.52M	$-7.61M	$-7.04M	$-6.74M	$-10.05M	$-5.43M	$-6.49M	$-7.03M	$-7.35M	$-5.47M	$-4.82M	$-1.63M	$-3.35M	$-4.08M
Avg Forecast	$-24.30M	$-21.90M	$-19.60M	$-17.40M	$-9.73M	$-7.93M	$-5.67M	$-4.80M	$-4.18M	$-3.00M	$-2.64M	$-2.44M	$-1.97M	$-2.20M	$-2.13M	$-2.12M	$-2.67M	$-2.41M	$-2.02M	$-8.23M	$-2.79M	$-3.57M	$-2.20M	$-4.42M	$-2.31M	$-1.71M	$-737.22K	$-2.02M	$-2.08M	$-1.16M
High Forecast	$-19.08M	$-17.20M	$-15.39M	$-13.66M	$-7.64M	$-6.23M	$-4.45M	$-3.36M	$-4.13M	$-2.36M	$-2.07M	$-1.91M	$-1.55M	$-1.73M	$-1.68M	$-1.66M	$-2.10M	$-2.41M	$-2.02M	$-6.58M	$-2.79M	$-3.57M	$-2.20M	$-3.54M	$-2.31M	$-1.71M	$-737.22K	$-1.62M	$-2.08M	$-1.16M
Low Forecast	$-32.40M	$-29.20M	$-26.13M	$-23.20M	$-12.98M	$-10.58M	$-7.56M	$-6.24M	$-4.23M	$-4.01M	$-3.52M	$-3.25M	$-2.63M	$-2.93M	$-2.84M	$-2.82M	$-3.56M	$-2.41M	$-2.02M	$-9.87M	$-2.79M	$-3.57M	$-2.20M	$-5.31M	$-2.31M	$-1.71M	$-737.22K	$-2.43M	$-2.08M	$-1.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.94%	2.06%	3.15%	3.49%	0.82%	3.60%	1.52%	2.96%	1.59%	3.18%	3.20%	6.54%	0.80%	1.61%	3.51%

undefined analysts predict PROF's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Profound Medical's previous annual EBITDA (undefined) of $NaN.

Profound Medical Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	6	4	4	7	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-6.74M	$-9.53M	$-5.00M	$-5.93M	$-8.21M	$-10.16M	$-6.00M	$-7.04M	$-7.50M	$-7.36M	$-6.08M	$-5.38M	$-2.54M	$-4.10M	$-4.74M
Avg Forecast	-	-	-	-	$-7.24M	$-8.22M	$-9.32M	$-10.20M	$-11.05M	$-9.99M	$-9.49M	$-9.95M	$-10.20M	$-11.30M	$-11.47M	$-11.78M	$-12.34M	$-12.70M	$-12.47M	$-8.79M	$-11.06M	$-8.99M	$-8.87M	$-4.72M	$-9.32M	$-7.96M	$-7.56M	$-3.16M	$-14.14M	$-12.03M
High Forecast	-	-	-	-	$-5.22M	$-5.93M	$-6.72M	$-8.34M	$-10.44M	$-7.20M	$-6.84M	$-7.17M	$-8.38M	$-8.14M	$-8.27M	$-8.49M	$-8.90M	$-12.70M	$-12.47M	$-7.03M	$-11.06M	$-8.99M	$-8.87M	$-3.78M	$-9.32M	$-7.96M	$-7.56M	$-2.53M	$-14.14M	$-12.03M
Low Forecast	-	-	-	-	$-10.37M	$-11.79M	$-13.36M	$-11.74M	$-11.67M	$-14.31M	$-13.61M	$-14.26M	$-11.66M	$-16.20M	$-16.44M	$-16.88M	$-17.69M	$-12.70M	$-12.47M	$-10.55M	$-11.06M	$-8.99M	$-8.87M	$-5.67M	$-9.32M	$-7.96M	$-7.56M	$-3.79M	$-14.14M	$-12.03M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.57%	0.77%	0.39%	0.48%	0.93%	0.92%	0.67%	0.79%	1.59%	0.79%	0.76%	0.71%	0.80%	0.29%	0.39%

Profound Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PROF's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Profound Medical SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	6	4	4	7	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.21M	$3.77M	$4.59M	$5.03M	$4.55M	$5.53M	$4.54M	$4.18M	$3.72M	$3.45M	$3.03M	$2.67M	$3.04M	$2.99M	$2.21M
Avg Forecast	$55.56M	$50.08M	$44.82M	$39.79M	$22.26M	$18.14M	$12.96M	$10.98M	$9.56M	$6.87M	$6.04M	$5.58M	$4.51M	$5.03M	$4.88M	$4.84M	$6.11M	$5.54M	$4.63M	$4.03M	$6.40M	$8.19M	$5.04M	$2.34M	$5.30M	$3.93M	$1.69M	$2.05M	$4.78M	$2.67M
High Forecast	$74.08M	$66.77M	$59.75M	$53.05M	$29.67M	$24.19M	$17.28M	$14.27M	$9.67M	$9.16M	$8.05M	$7.43M	$6.01M	$6.70M	$6.50M	$6.45M	$8.15M	$5.54M	$4.63M	$4.03M	$6.40M	$8.19M	$5.04M	$2.81M	$5.30M	$3.93M	$1.69M	$2.05M	$4.78M	$2.67M
Low Forecast	$43.63M	$39.32M	$35.19M	$31.24M	$17.48M	$14.24M	$10.17M	$7.68M	$9.45M	$5.39M	$4.74M	$4.38M	$3.54M	$3.95M	$3.83M	$3.80M	$4.80M	$5.54M	$4.63M	$4.03M	$6.40M	$8.19M	$5.04M	$1.87M	$5.30M	$3.93M	$1.69M	$2.05M	$4.78M	$2.67M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	0.62%	0.83%	1.09%	1.13%	0.86%	0.55%	0.83%	1.59%	0.65%	0.77%	1.58%	1.48%	0.62%	0.83%

Profound Medical's average Quarter SG&A projection for Jun 23 is $4.88M, based on 2 Wall Street analysts, with a range of $3.83M to $6.50M. The forecast indicates a 15.84% rise compared to PROF last annual SG&A of $4.21M (Mar 23).

Profound Medical EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	3	2	2	2	5	2	2	2	1	3	3	3	4	4	4	4	4	6	4	4	7	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.32	$-0.46	$-0.24	$-0.29	$-0.40	$-0.50	$-0.29	$-0.35	$-0.37	$-0.39	$-0.32	$-0.34	$-0.18	$-0.28	$-0.43
Avg Forecast	-	-	-	-	$-0.29	$-0.33	$-0.38	$-0.41	$-0.45	$-0.41	$-0.39	$-0.40	$-0.41	$-0.46	$-0.47	$-0.48	$-0.50	$-0.52	$-0.51	$-0.56	$-0.45	$-0.37	$-0.36	$-0.34	$-0.38	$-0.33	$-0.31	$-0.38	$-0.58	$-0.49
High Forecast	-	-	-	-	$-0.21	$-0.24	$-0.27	$-0.34	$-0.42	$-0.29	$-0.28	$-0.29	$-0.34	$-0.33	$-0.34	$-0.34	$-0.36	$-0.52	$-0.51	$-0.56	$-0.45	$-0.37	$-0.36	$-0.34	$-0.38	$-0.33	$-0.31	$-0.38	$-0.58	$-0.49
Low Forecast	-	-	-	-	$-0.42	$-0.48	$-0.54	$-0.48	$-0.47	$-0.58	$-0.55	$-0.58	$-0.47	$-0.66	$-0.67	$-0.68	$-0.72	$-0.52	$-0.51	$-0.56	$-0.45	$-0.37	$-0.36	$-0.34	$-0.38	$-0.33	$-0.31	$-0.38	$-0.58	$-0.49
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.67%	0.92%	0.46%	0.57%	0.72%	1.11%	0.79%	0.96%	1.07%	1.03%	0.99%	1.09%	0.47%	0.48%	0.88%

According to undefined Wall Street analysts, Profound Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PROF previous annual EPS of $NaN (undefined).

Profound Medical Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
NVRO	Nevro	-	-	623.89%	Hold
SGHT	Sight Sciences	-	-	124.44%	Hold
PROF	Profound Medical	-	-	88.74%	Buy
LUNG	Pulmonx	-	-	75.70%	Buy
SIBN	SI-BONE	-	-	59.24%	Buy
KIDS	OrthoPediatrics	-	-	50.34%	Buy
LIVN	LivaNova	-	-	37.37%	Buy
NPCE	NeuroPace	-	-	32.78%	Buy
OFIX	Orthofix Medical	-	-	26.92%
FNA	Paragon 28	-	-	14.54%	Buy
IRMD	IRadimed	-	-	12.72%	Buy
CVRX	CVRx	-	-	9.97%	Buy
AORT	Artivion	-	-	8.24%	Buy
SRDX	Surmodics	-	-	0.43%	Buy
ITGR	Integer	-	-	-0.08%	Buy

PROF Forecast FAQ

Is Profound Medical a good buy?

Yes, according to 2 Wall Street analysts, Profound Medical (PROF) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PROF's total ratings.

What is PROF's price target?

Profound Medical (PROF) average price target is $14.25 with a range of $12 to $16.5, implying a 88.74% from its last price of $7.55. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Profound Medical stock go up soon?

According to Wall Street analysts' prediction for PROF stock, the company can go up by 88.74% (from the last price of $7.55 to the average price target of $14.25), up by 118.54% based on the highest stock price target, and up by 58.94% based on the lowest stock price target.

Can Profound Medical stock reach $11?

PROF's average twelve months analyst stock price target of $14.25 supports the claim that Profound Medical can reach $11 in the near future.

What are Profound Medical's analysts' financial forecasts?

Profound Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.13M (high $37.35M, low $21.68M), average EBITDA is $-28.133M (high $-21.682M, low $-37.349M), average net income is $-34.976M (high $-26.203M, low $-47.256M), average SG&A $64.33M (high $85.4M, low $49.58M), and average EPS is $-1.419 (high $-1.063, low $-1.918). PROF's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $83.2M (high $110.93M, low $65.33M), average EBITDA is $-83.2M (high $-65.33M, low $-111M), average net income is $0 (high $0, low $0), average SG&A $190.25M (high $253.65M, low $149.38M), and average EPS is $0 (high $0, low $0).

Did the PROF's actual financial results beat the analysts' financial forecasts?

Based on Profound Medical's last annual report (Dec 2022), the company's revenue was $6.68M, which missed the average analysts forecast of $8.86M by -24.58%. Apple's EBITDA was $-25.474M, beating the average prediction of $-15.328M by 66.19%. The company's net income was $-28.669M, missing the average estimation of $-46.302M by -38.08%. Apple's SG&A was $17.93M, missing the average forecast of $20.31M by -11.72%. Lastly, the company's EPS was $-1.4, missing the average prediction of $-2.09 by -33.01%. In terms of the last quarterly report (Mar 2023), Profound Medical's revenue was $1.86M, missing the average analysts' forecast of $2.12M by -12.13%. The company's EBITDA was $-6.219M, beating the average prediction of $-2.117M by 193.81%. Profound Medical's net income was $-6.741M, missing the average estimation of $-11.776M by -42.76%. The company's SG&A was $4.21M, missing the average forecast of $4.84M by -13.00%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-0.478 by -33.04%